Introduction
Im Neuenheimer Feld 280, 69120 Heidelberg, Germany, 2 Department of Biochemistry, Faculty of Natural Sciences, Charles University, Chinese herbs nephropathy (CHN*) is a recently described 12840 Prague, The Czech Republic and Departments of 3 Pathology and subacute interstitial disease associated with the prolonged use 4 Renal Diseases, University of Louvain Medical School, Cliniques Universitaires St-Luc, 10 Avenue Hippocrate, 1200 Bruxelles, Belgium of Chinese herbs during a slimming cure. Over 80 patients have been identified, half of whom needing renal replacement 5 To whom correspondence should be addressed therapy including renal transplantation (1) (2) (3) (4) . The absence in Recently, we reported that aristolochic acid (AA) a naturthe delivered capsules of one of the prescribed Chinese herbs ally occurring nephrotoxin and carcinogen is implicated in (Stephania tetrandra) taken together with the identification of a unique type of renal fibrosis, designated Chinese herbs aristolochic acid (AA), the major alkaloid of Aristolochia nephropathy (CHN). Indeed, we identified the principal species, in 11 out of 12 different samples of herb powders aristolochic acid-DNA adduct in the kidney of five such imported in Belgium under the name of Stephania tetrandra patients. We now extend these observations and demon- (5) led to the suggestion that Stephania tetrandra had been strate the presence of additional AA-DNA adducts by the replaced accidentally by Aristolochia fangchi, another Chinese 32 P-post-labelling method not only in the kidneys, but also herb. However, AA had not been identified initially in the in a ureter obtained after renal transplantation. Using the capsules delivered to the patients probably as a result of an nuclease P1 version of the assay not only the major inadequate extraction procedure (5) .
DNA adduct of aristolochic acid, 7-(deoxyadenosin-N 6 -yl)-
The active principle extracted from Aristolochia plants is aristolactam I (dA-AAI), but also the minor adducts, aristolochic acid (AA). AA is a mixture consisting of structur-7-(deoxyguanosin-N 2 -yl)-aristolactam I (dG-AAI) and 7-ally related nitrophenanthrene carboxylic acids, AAI and AAII (deoxyadenosin-N 6 -yl)-aristolactam II (dA-AAII) were being the major components. AA has been shown to stimulate detected, and identified by cochromatographic analyses various defense mechanisms and to exert antiviral, antibacterial with TLC and HPLC. Quantitative analyses of six kidneys and even anti-neoplastic properties in certain animal models revealed relative adduct levels from 0.7 to 5.3/10 7 for dA- (6) (7) (8) . High doses of AA are nephrotoxic in animals (9) and AAI, from 0.02 to 0.12/10 7 for dG-AAI and 0.06 to 0.24/ in humans (10) prohibiting its use in cancer therapy (11) . In 10 7 nucleotides for dA-AAII. The detection of the dA-AAII 1982 the natural mixture AA was shown to be a strong adduct is consistent with the occurrence of aristolochic carcinogen in rodents (12, 13) . Its carcinogenic and mutagenic acid II (AAII) in the herb powder imported under the effects (14,15) were found to be associated with the formation name of Stephania tetrandra and confirms that the patients of AA DNA adducts. The main DNA adducts formed by AA had indeed ingested the natural mixture of AAI and AAII.
in vitro were identified by us as the aristolactam structures 32 P-post-labelling analyses of further biopsy samples of one bound to the exocyclic amino groups of deoxyguanosine and patient showed the known adduct pattern of AA exposure deoxyadenosine (16, 17) . not only in the kidney, but also in the ureter, whereas in Recently, we demonstrated that AA had indeed been ingested skin and muscle tissue no adduct spots were detectable. In by the CHN patients: we identified the presence of one AAan attempt to explain the higher level of the dA-AAI adduct DNA adduct [7- (deoxyadenosin-N 6 -yl)-aristolactam I (dAcompared to the dG-AAI adduct level in renal tissue even AAI)] in the kidneys of five patients by 32 P-post-labelling 44 months after the end of regimen, the persistence of (18). We now extend these observations in eight kidneys from these two purine adducts was investigated in the kidney of six patients by the identification of two additional AA-DNA rats given a single oral dose of pure AAI. In contrast to adducts whose structure is elucidated. Furthermore, we demonthe dG-AAI adduct, the dA-AAI adduct exhibited a lifelong strate the presence of these three adducts in the ureter, but not persistence in the kidney of rats. Our data demonstrate in the muscle or skin of a patient with CHN. Finally, we that AA forms DNA adducts in human tissue by the same conclude from an animal study that each AA adduct has its activation mechanism(s) reported from animal studies.
own kinetic characteristics accounting for the fact that only Thus, the carcinogenic/mutagenic activity of AA observed one adduct remains in tissues for an extensive period of time. Eight native kidneys were taken from six patients with documented CHN undergoing transplantation and treated as described (18). Corticomedullary, PEI-cellulose, polyethyleneimine-cellulose; TLC, thin layer chromatography; HPLC, high performance liquid chromatography; RAL, relative adduct skin and muscle tissue samples, and the right ureter removed from one patient (case 6) were treated in the same manner. Similarly, corticomedullary samples labelling.
obtained from end-stage kidneys removed from six patients at the time of transplantation were used as controls as reported before (18).
Identification of AAI and AAII in herbal powders
Herbal powders (170 mg) delivered in Belgium under the name of S.tetrandra were extracted by treatment with 5 ml methanol. The methanolic extract was concentrated to 2.5 ml and aliquots (50 or 100 µl) were analysed by high performance liquid chromatography (HPLC). Separation was performed on a reversed phase column (Beckman Ultasphere ODS RP18, 5 µm) using a linear gradient from 5 to 50% acetonitrile in 0.1 M triethylammoniumacetate, pH 7.0, within 45 min at a flow rate of 1 ml/min. Retention times of AAI (30.0 
P-post-labelling analysis
The method has been described elsewhere (19). DNA was isolated by phenol extraction. DNA samples (12.5 µg) were digested, enriched and analysed by 32 P-post-labelling as described (20). Adducts and normal nucleotides were detected by autoradiography and spots were excised from the chromatograms for Cerenkov counting. Count rates of adducted fractions were determined from triplicate maps after subtraction of count rates from adjacent blank areas. Excess [γ-32 P]ATP after the post-labelling reaction was confirmed. Adduct levels were calculated in units of relative adduct labelling (RAL) as reported before (19).
Preparation of reference compounds dAp-AAI, dGp-AAI and dAp-AAII were prepared by incubations with the 3Ј-monophosphates deoxyadenosine-3Ј-monophosphate (dAp) or deoxyguanosine-3Ј-monophosphate (dGp) and AAI or AAII activated by xanthine oxidase as described (20). Twenty-microlitre aliquots of the incubations were directly used for the n-butanol extraction-mediated 32 P-post-labelling method described by Gupta and Earley (21). TLC and quantitation of adducts were performed as described (20). Chromatographic conditions as in Figure 1 . One case with lupus nephritis has in 100 µl methanol/phosphate buffer, pH 3.5, 1:1 (v/v). Aliquots (50 µl) were been reported previously (18). analysed on a phenyl-modified reversed-phase column (250ϫ4.6 mm, 5 µm Zorbax Phenyl; Säulentechnik Dr Knauer, Berlin, Germany) with a linear gradient of methanol (from 40 to 80% in 45 min) in aqueous 0.5 M sodium and two minor spots (spots 2 and 3) illustrated in Figure 1 . phosphate and 0.5 M phosphoric acid, pH 3.5, at a flow rate of 0.9 ml/min. Radioactivity eluting from the column was measured by monitoring Cerenkov Details on the major spot have been presented before for five radiation with a Berthold LB 506 C-1 HPLC radioactivity monitor (500 µl patients (18). The two minor spots were detectable only after cell, dwell time 6 s).
Co-chromatography on PEI-cellulose
prolonged exposure time. The levels of the three DNA adducts ranged from 0.7 to 5.3 /10 7 nucleotides for spot 1, from 0.02 Results to 0.12/10 7 for spot 2 and from 0.06 to 0.24/10 7 for spot 3. By contrast, DNA isolated from the kidneys of patients with Detection of AAI and AAII in herbal powders several other renal diseases was virtually free of spots in Three different samples of herb powders delivered in Belgium the area where adducts associated with CHN were located under the name of S.tetrandra were analysed for the presence (Figure 2 ). In two patients (Figure 2b and c) a diffuse band of of aristolochic acids (22). Similar batches have been used for radioactivity, the typical smoking-related adduct pattern (23), the preparation of capsules (in reference 1 called 'formula 2 known as diagonal radioactive zone (DRZ) with total adduct pills') prescribed during the slimming cure (18). Two of levels of~1/10 7 nucleotides was observed. the three samples contained AAI and AAII in amounts of DNA adduct identification approximately 2 mg/g and 0.2 mg/g, respectively. Traces of It was clear from the cochromatographic analysis on polyethylthe corresponding aristolactams were also detectable (data eneimine (PEI) plates shown in Figure 3 that adduct spots 1,2 not shown). and 3 obtained from human kidneys were chromatographically DNA adduct detection indistinguishable from reference adduct spots identified previously as AAI-and AAII-modified nucleosides. Thus, spot 1 The renal samples from six patients with CHN revealed identical adduct patterns consisting of one major spot (spot 1) was assigned as 3Ј,5Ј-bisphospho-7-(deoxyadenosin-N 6 -yl)- concentration, followed by the dA-AAII adduct and the dG- Additional tissue samples of the ureter, muscle and skin, obtained in case 6 during transplantation, were analysed by aristolactam I (dA-AAI), spot 2 as 3Ј,5Ј-bisphospho-7-(deoxyg-32 P-post-labelling. In the ureter the characteristic adduct pattern uanosin-N 2 -yl)-aristolactam I (dG-AAI) and spot 3 as 3Ј,5Ј-of AA was found ( Figure 5 ), whereas muscle and skin samples bisphospho-7-(deoxyadenosin-N 6 -yl)-aristolactam II (dAexhibited no AA specific adduct spots (data not shown). RAL AAII).
values for the adducts in the ureter were in the same range as As a second, independent chromatographic procedure to for the kidneys with dA-AAI being the major adduct. confirm identities of adduct spots we employed reversed-phase HPLC analysis. The results thus obtained confirmed findings
Persistence of dA-AAI in renal tissue of rats produced by cochromatography on PEI plates. Results for spot
The stability of dA-AAI and dG-AAI in rat kidney was 1 and the dA-AAI standard have been previously reported examined up to 36 weeks after a single oral dose (5 mg/kg (18). Spot 3 eluted with a retention time of 18.3 min, identical body weight) of pure AAI ( Figure 6 ) as described before for to the dA-AAII standard (Figure 4a and b) . When equal other organs like forestomach, glandular stomach, lung, liver amounts of radioactivity from spot 3 and the reference comand urinary bladder (24). Both purine AAI-DNA adducts pound dA-AAII were mixed prior to analysis a single spot remained detectable in the kidney for up to 36 weeks. After a was found (Figure 4c ). Spot 2 eluted as three peaks one of rapid decrease of dA-AAI and dG-AAI levels during the first them with the identical retention time of the dG-AAI standard 2 weeks (~50 % of the adducts observed at day 1 are removed), (17.1 min) and one with the retention time of the dA-AAI dG-AAI adducts continued to disappear, whereas dA-AAI standard (22.5 min). The compound eluting with a retention levels (25% of the adducts observed at day 1) remained time of 13.5 min is unknown (Figure 4d,e) . When the spot 2 practically unchanged between 4 and 36 weeks ( Figure 6 ). sample was spiked with the dG-AAI standard only the peak Similar removal curves with a triphasic profile have been at 17.1 min increased (Figure 4f) .
reported for the target organ forestomach and the non-target Quantitative analysis of the three identified AA-DNA adducts in renal tissue from six CHN patients (Table I) revealed organs liver and lung (24). RAL values of the dG-AAI adduct are corrected to one-third of the radioactivity due to the contamination with dA-AAI adduct and an unknown compound found in all HPLC determinations (as shown in Figure 4e) . and demonstrate that this was under both forms of aristolochic acid, AAI and AAII. The compound provided was thus the natural mixture similar to that we have recognized in herbal reports on rats given pure AAI or the natural mixture AA (20,25). Irrespective of the tissue analysed in those animal powders. 32 P-post-labelling analyses of all six patients with CHN displayed identical adduct patterns, characteristic for AA studies dA-AAI was always the predominant adduct. The persistence of two purine DNA adducts of AAI in exposure, in the kidneys and in one ureter. By contrast, 32 Ppost-labelling analyses of renal tissues obtained from six several rat organs has been previously investigated (24). Since the kidney was not included in this former study we here present patients with renal failure of other causes did not show such patterns. In two patients the complex pattern of adduct spots the long-term persistence of the dA-AAI and dG-AAI adducts in this organ. The differential rates of disappearance of dGand areas of unresolved radioactivity, typical for smokingrelated DNA adducts, was observed. At inquiry one patient AAI adducts versus dA-AAI adducts show that removal kinetics in the third phase (16-36 weeks) are not solely (Figure 2c ) was identified as a heavy smoker (1 pack per day for 15 years). It is worth mentioning that no smoking related a function of cell turnover. Such triphasic decline characteristics have been reported for other carcinogens, including 7,12-adduct spots were detectable in samples of three CHN patients known to have been heavy smokers before renal transplantation dimethylbenz 
